Techinvest: “trading in line with expectations… maiden profit”
Posted by markturrell on May 11, 2009
Imaginatik 4.75p
(IMTK: AIM, Tech Software & Services)
The Company has signed a contract extension with long-standing customer, Pfizer. The agreement will ensure the long-term ongoing use of Imaginatik’s Idea Central software within Pfizer’s Research and Development division. The Company also announced that results for the year to March 31 will be in line with expectations and a maiden operating profit is anticipated for the period.
Analyst George O’Connor at Broker Panmure Gordon commented during the month that Imaginatik is a company with plenty of upside potential and management that “looks in their stride”.
Continue to hold.
Source: Techninvest, Fri 1 May 2009
